



## Erwinaze<sup>®</sup> (asparaginase *Erwinia chrysanthemi*) – Drug Shortage

- The [drug shortage](#) of [Jazz's Erwinaze \(asparaginase \*Erwinia chrysanthemi\*\)](#) is ongoing. Erwinaze has been unavailable for at least 90 days. Jazz estimates product will be available for ordering by the end of November or early December, at the earliest.
- Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to *E. coli*-derived asparaginase.

| Product Description   | NDC #        |
|---|--------------|
| Erwinaze 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial (5 vial carton) | 57902-249-05 |
| Erwinaze 10,000 IU lyophilized powder supplied in a clear 3 mL glass vial (1 vial)        | 57902-249-01 |

- Jazz has also provided a [Dear Healthcare Provider letter](#) regarding special handling instructions for certain Erwinaze products due to the potential for particulate matter.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.